← All trials
NCT06774144
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 15, 2025
- Primary completion
- Dec 31, 2028
- Completion date
- Dec 31, 2028
- First posted
- Jan 14, 2025
- Last posted
- Oct 17, 2025
- Enrollment
- 385
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of PittsburghLead sponsor
- University of PittsburghSponsor investigator
- University of PittsburghOfficial
- Melinta TherapeuticsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.